


AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of the claims.

Claims 1-36. (Cancelled)

Claim 37. (Previously Presented) A 2-acylaminothiazole derivative compound represented by the following Formula (V), or a pharmaceutically acceptable salt thereof:




wherein the symbols have the following meanings:

Ar²: substituted or unsubstituted phenyl or monocyclic aromatic heterocycle;

R³: a substituted or unsubstituted thienyl;

R⁴: a group represented by Formula II:



wherein X is C(R²⁷)R²⁸ or NR²⁶ and m=n=2;

wherein CR²⁰R²¹ and CR²²R²³ can be identical or different; and

wherein each of R²⁰, R²¹, R²², R²³, R²⁶, R²⁷, and R²⁸ can be the same or different and can be selected from the group consisting of -H; -OH; -O-lower alkyl; a substituted or unsubstituted lower alkyl; a substituted or unsubstituted cycloalkyl; a substituted or unsubstituted aryl; a substituted or unsubstituted arylalkyl; a substituted or unsubstituted aromatic heterocycle; a substituted or unsubstituted aromatic heterocyclic alkyl; a substituted or unsubstituted nonaromatic heterocycle; lower alkenyl; lower alkylidene; -COOH; -COO-lower alkyl; -COO-lower alkenyl; -COO-lower alkylene-aryl; -COO-lower alkylene-aromatic heterocycle; carbamoyl or amino, each of which can be substituted with one or more groups selected from the group consisting of lower alkyl

which can be substituted with halogen, -OH, -O-lower alkyl, or -O-aryl; -NHCO-lower alkyl; and oxo.

Claim 38. (Previously Presented) The compound according to claim 37, wherein Ar² is phenyl or pyridyl, each of which can be substituted.

Claim 39. (Previously Presented) The compound according to claim 37, wherein R³ is a thienyl which is substituted with 1 to 3 halogen atoms, which can be identical or different.

Claim 40. (Currently Amended) The compound according to claim 39[[37]], wherein R⁴ is 4-(piperidin-1-yl)piperidin-1-yl, 4-propylpiperidin-1-yl, 4-cyclohexylpiperazin-1-yl, or 4-propylpiperazin-1-yl.

Claim 41. (Currently Amended) The compound according to claim 40[[37]], wherein Ar² is phenyl which is unsubstituted at 2- and 6-positions, substituted with -H, -F, -Cl, or -Br at 3-position, substituted with -F, -Cl, or -Br at 5-position, and substituted at 4-position; or pyridin-3-yl which is unsubstituted at 2- and 4-positions, substituted with -F, -Cl, or -Br at 5-position, and substituted at 6-position.

Claim 42. (Currently Amended) The compound according to claim 41[[37]], wherein Ar² is phenyl which is substituted at 4-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, a substituted or unsubstituted piperidin-1-yl and a substituted or unsubstituted piperazin-1-yl; or pyridin-3-yl which is substituted at 6-position with a group selected from the group consisting of -O-R^Y, -NH-R^Y, a substituted or unsubstituted piperidin-1-yl and a substituted or unsubstituted piperazin-1-yl, wherein R^Y is lower alkyl which can be substituted with one or more groups selected from the group consisting of -OH, -O-lower alkyl, amino which can be substituted with one or two lower alkyl, -CO₂H, -CO-lower alkyl, carbamoyl which can be substituted with one or two lower alkyl, cyano, aryl, aromatic heterocycle, nonaromatic heterocycle and halogen.

Claim 43. (Currently Amended) The compound according to any one of claims [[5, 25 and]] 37-42 wherein the pharmaceutically acceptable salt is a maleate salt.


Claim 44. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of any one of the pharmaceutical compounds of claims 37-42, 5, 7, 9, 13 and 18-42 and a pharmaceutically acceptable carrier.

Claim 45. (Previously Presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 43 and a pharmaceutically acceptable carrier.

Claim 46. (Previously Presented) The pharmaceutical composition according to claim 44, wherein the pharmaceutical composition is formulated for oral administration.


Claim 47. (Previously Presented) The pharmaceutical composition according to claim 45, wherein the pharmaceutical composition is formulated for oral administration.

Claim 48. (New) A pharmaceutical composition for treating thrombocytopenia, the composition comprising: a therapeutically effective amount of a compound selected from the group consisting of



and pharmaceutically acceptable salts thereof; and
a pharmaceutically acceptable carrier.

Claim 49. (New) The pharmaceutical composition of claim 48, wherein the compound is:



Claim 50 (New) A compound selected from the group consisting of: 1-(3-chloro-5-{{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbonyl}-2-pyridyl)piperidine-4-carboxylic acid, and pharmaceutically acceptable salts thereof.

Claim 51. (New) The compound of claim 51, wherein the pharmaceutically acceptable salt is the maleic acid salt.